← Eichor
Study identifier: NCT05629026 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema

Condition: Lymphedema  ·  Sponsor: University Hospital, Toulouse

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.

This description comes directly from the study's public registry record.

Talk to the study team

Julie MALLOIZEL-DELAUNAY, MD  ·  +33 (0)5 61 32 30 33  ·  malloizel-delaunay.j@chu-toulouse.fr

Charline DAGUZAN  ·  +33 (0)5 61 77 84 99  ·  daguzan.c@chu-toulouse.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Toulouse HospitalToulouse, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05629026